Eribulin
From Wikipedia, the free encyclopedia
 |
|
|
Eribulin
|
|
| Systematic (IUPAC) name | |
| 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C40H59NO11 |
| Mol. mass | 729.90 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Eribulin (INN, codenamed E7389) is an investigational anti-cancer drug. It is currently being investigated by Eisai for the third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine. Eribulin is a synthetic analogue of halichondrin B, a potent, natural mitotic inhibitor with an unique mechanism of action found in the Halichondria genus of sponges.[1]
On February 1, 2008, Eisai announced a change in the schedule for submission to the US Food and Drug Administration (FDA) of a New Drug Application (NDA) for eribulin.[2]
[edit] References
- ^ Kuznetsov G, Towle MJ, Cheng H, et al (August 2004). "Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389". Cancer Res 64 (16): 5760–6. doi:. PMID 15313917.
- ^ Drugs.com, Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application. Retrieved on 2008-02-06.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
